HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:

Title: Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer
Authors: Kinoshita, Rumiko Browse this author →KAKEN DB
Mitamura, Takashi Browse this author →KAKEN DB
Kato, Fumi Browse this author
Hattori, Takahiro Browse this author
Higaki, Hajime Browse this author
Takahashi, Shuhei Browse this author
Fujita, Yoshihiro Browse this author
Otsuka, Manami Browse this author
Koizumi, Fuki Browse this author
Uchinami, Yusuke Browse this author
Mori, Takashi Browse this author
Nishioka, Kentaro Browse this author
Hashimoto, Takayuki Browse this author
Ito, Yoichi M. Browse this author
Watari, Hidemichi Browse this author
Aoyama, Hidefumi Browse this author →KAKEN DB
Keywords: cervical cancer
definitive radiotherapy
human papilloma virus (HPV) genotype
Issue Date: Mar-2023
Publisher: Oxford University Press
Journal Title: Journal of Radiation Research
Volume: 64
Issue: 2
Start Page: 463
End Page: 470
Publisher DOI: 10.1093/jrr/rrac086
Abstract: Most oncogenic human papilloma virus (HPV) genotypes stratify into two species, alpha-7 HPV and alpha-9 HPV. There are several studies that evaluate the relationship between HPV species and treatment outcomes and reports that HPV species is prognostic. The HPV genotyping was conducted using biopsy specimens which had been stored in these studies. We conducted the study using the HPV test performed by cytology specimens which is less invasive and more useful in clinical settings. This study enrolled 46 patients who received HPV genotyping before the definitive radiotherapy. The results of the HPV genotyping were classified into HPV alpha-7, HPV alpha-9 and negatives. Of the 46 patients, 10 were positive for HPV alpha-7, 21 positive for HPV alpha-9 and 15 were negative. The median follow-up period was 38 months (range 4-142). The HPV alpha-7, HPV alpha-9 and negative groups showed the 3-year overall survival (OS; 59.3%, 80.4% and 72.2% [P = 0.25]); local control (LC; 67.5%, 81% and 80% [P = 0.78]); pelvic control (PC) (50%, 81% and 72.7% [P = 0.032]); pelvic lymph node (PLN) control (78.7%, 95% and 92.3% [P = 0.012]); distant metastasis free (DMF) survival (50%, 75.4% and 42.8% [P = 0.098]); and progression free survival (PFS) rate of patients (30%, 66.7% and 38.9% [P = 0.085]), respectively. Patients with HPV alpha-7 showed statistically significant poorer PC than the HPV alpha-9 group, in multivariate analysis. This result is consistent with previous studies for HPV positive patients. The HPV negativity rate was higher in this study than in other studies and further work on this may be needed for clinical use.
Type: article
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University